Celltrion gains EC approval for Avtozma, a RoActemra biosimilar for autoimmune diseases

Celltrion has received marketing authorization from the European Commission (EC) for Avtozma, a biosimilar to RoActemra (tocilizumab), expanding the company’s footprint in the immunology and ... Read More